Drug Information

Drug (ID: DG02163) and It's Reported Resistant Information

• Name: MA-D1
• Synonyms: MA-D1
• Indication:
  In total 1 Indication(s)
  . .; .; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Staphylococcus meningitis [ICD-11: 1B54]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Glucosamine-fructose-6-phosphate aminotransferase (GlmS) [1]

• Sensitive Disease: Staphylococcus aureus infection [ICD-11: 1B54.0]
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Methicillin-resistant Staphylococcus aureus; 5833
• In Vitro Model: BABL/C female mice; 5833
• Experiment for Molecule Alteration: Gel-based protein profiling assay; MS analysis; Enzymatic activity assay; Thermal shift assay; SPR assay; RNA isolation assay; RT-PCR
• Experiment for Drug Resistance: Resistance development assay; Hemolysis assay; Cytotoxicity assay
• Mechanism Description: Marinopyrrole A derivative MA-D1 shows anti-MRSA activity by targeting GlmS to inhibit cell wall biosynthesis. This discovery provides a novel target and a lead for developing new antibiotics.

References

• Ref 1: An Optimized Marinopyrrole A Derivative Targets 6-Phosphoglucosamine Synthetase to Inhibit Methicillin-Resistant Staphylococcus aureus. ACS Cent Sci. 2024 Oct 25;10(11):2090-2098.